Article
Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
Circulation - 1 Apr 1993
Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann E J, Landsberger D, Sehayek E, Meiner V, Wurm M
Abstract excerpt
BACKGROUND: In familial hypercholesterolemia, plasma lipoproteins can be modulated by 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, although the underlying response mechanisms are still unknown. METHODS AND RESULTS: A single-blind study with fluvastatin, an HMG-CoA reductase inhibitor, was conducted in 64 familial hypercholesterolemia patients who had defined apolipoprotein E (apo E) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.